Dana-Farber's Guru Sonpavde, MD, provides insight on circulating tumor DNA trial in bladder cancer highlighted at ESMO 2021.
So what we had was 39 patients who had an immune checkpoint in a bit of in the setting of metastatic Euroclear carcinoma. And we had pre treatment and post treatment samples of plasma from all of these patients. To summarise the findings. The sensitivity of this platform was excellent. So 100% of patients at the baseline setting had some C. D. D. N. A. Detective and 95% of samples in the post treatment um population where we had samples had C. G. D. N. A. Detected in patients who were responding to the treatment. There was a extinction of these alterations found. For example P. 53 uh Victory C. A. B. R. C. A. One and two operations. They seem to go away or disappear in patients who were responding and the patients who are progressing new operations seem to appear again. We needed a larger data set to corroborate these data but I think that this is a highly sensitive and um interesting platform to further study the biology of this disease and to detect mechanisms of resistance.
Related Presenters
